We use cookies on this website. By continuing to use this site without changing your cookie settings, you agree that you are happy to accept our cookies and for us to access these on your device. Find out more about how we use cookies and how to change your cookie settings.

Emergence of artemisinin resistance on Thai-Myanmar border raises spectre of untreatable malaria

5 April 2012

Evidence that the most deadly species of malaria parasite, Plasmodium falciparum, is becoming resistant to the frontline treatment for malaria on the border of Thailand and Myanmar is reported in the ‘Lancet’ today. This increases concern that resistance could now spread to India and then Africa, as resistance to other antimalarial drugs has done before. Eliminating malaria might then prove impossible.

The study coincides with research published today in 'Science' in which researchers in South-east Asia and the USA identify a major region of the malaria parasite genome associated with artemisinin resistance. This region, which includes several potential candidate genes for resistance, may provide researchers with a tool for mapping resistance.

The studies, both funded by the Wellcome Trust and the US National Institutes of Health, follow reports in 2009 of the emergence of artemisinin-resistant malaria parasites in western Cambodia, 800 km away from the Thai-Myanmar border where the new cases of resistance have been observed. Resistance to artemisinin makes the drugs less effective and could eventually render them obsolete, putting millions of lives at risk.

According to the World Malaria Report 2011, malaria killed an estimated 655 000 people in 2010, mainly young children and pregnant women. Malaria is caused by parasites that are injected into the bloodstream by infected mosquitoes; Plasmodium falciparum is the parasite responsible for nine out of ten malaria deaths.

The most effective antimalarial drug is artemisinin. Artemisinin derivatives, such as artesunate, have several advantages over other antimalarial drugs such as chloroquine and mefloquine: the artemisinin derivatives act more rapidly, they have fewer side-effects and, until recently, malaria parasites have shown no resistance against them.

Although artemisinin derivatives can be used on their own - as a monotherapy - fears about the possible development of resistance led to recommendations that they should only be used in conjunction with one or more other drugs - as artemisinin-based combination therapies (ACTs).

ACTs are now recommended by the World Health Organization as the firstline treatment for uncomplicated falciparum malaria in all countries where the disease is endemic, and they have contributed substantially to the recent decline in malaria cases in most tropical endemic regions.

The 'Lancet' study was carried out over the ten years from 2001 to 2010 by researchers at the Shoklo Malaria Research Unit on the border of Thailand and Myanmar, part of the Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme. They measured how long it took to clear parasites from the bloodstream in 3202 patients with falciparum malaria using oral artesunate-containing medications.

Over the ten years, the average time taken to reduce the number of parasites in the blood by a half - known as the 'parasite clearance half-life' - increased from 2.6 hours in 2001 to 3.7 hours in 2010, a clear sign that the drugs were becoming less effective. The proportion of infections that were slow-clearing - those with a half-life of more than 6.2 hours - increased over the decade from six in 1000 to 200 in 1000.

By examining the genetic make-up of the parasites, the researchers were able to provide compelling evidence that the decline in the parasite clearance rates was due to genetic changes in the parasites, which had made them resistant to the drugs.

This finding is supported by the evidence reported in 'Science', in which the same researchers, together with an international team led by scientists at the Texas Biomedical Research Institute, San Antonio, identified a region on chromosome 13 of the P. falciparum parasite genome that shows a strong association with slow parasite clearance. Although the actual mechanism involved is not clear, the region contains several candidate genes that may confer artemisinin resistance to the parasite.

Professor François Nosten, Director of the Shoklo Malaria Research Unit, said: "We have now seen the emergence of malaria resistant to our best drugs, and these resistant parasites are not confined to western Cambodia. This is very worrying indeed and suggests that we are in a race against time to control malaria in these regions before drug resistance worsens and develops and spreads further.

"The effect of that happening could be devastating. Malaria already kills hundreds of thousands of people a year - if our drugs become ineffective, this figure will rise dramatically."

Professor Nick White, Chairman of the Wellcome Trust's South-east Asia Major Overseas Programmes and Chair of the Worldwide Antimalarial Resistance Network, added: "Initially we hoped we might prevent this serious problem spreading by trying to eliminate all P. falciparum from western Cambodia. While this could still be beneficial, this new study suggests that containing the spread of resistance is going to be even more challenging and difficult than we had first feared."

Dr Tim Anderson from the Texas Biomedical Research Institute, who led the genetics studies in both papers, commented: "Mapping the geographical spread of resistance can be particularly challenging using existing clinical and parasitology tools. If we can identify the genetic determinants of artemisinin resistance, we should be able to confirm potential cases of resistance more rapidly. This could be critically important for limiting further spread of resistance.

"We know that the genome region identified harbours a number of potential genes to explore further to see which ones drive artemisinin resistance. If we can pinpoint the precise gene or genes, we can begin to understand how resistance occurs."

Dr Jimmy Whitworth, Head of International Activities at the Wellcome Trust, said: "These two studies highlight the importance of being vigilant against the emergence of drug resistance. Researchers will need to monitor these outbreaks and follow them closely to make sure they are not spreading.

"Preventing the spread of artemisinin resistance to other regions is imperative, but as we can see here, it is going to be increasingly difficult. It will require the full force of the scientific and clinical communities, working together with health policy makers."

Image: A wall capillary in the lung of a person with falciparum malaria. Plasmodium falciparum parasites can be seen in the red blood cells. Credit: Wellcome Images.

Contact

Craig Brierley
Senior Media Officer
Wellcome Trust
T
+44 (0)20 7611 7329
E
c.brierley@wellcome.ac.uk

Notes for editors

References

  • Phyo AP et al. Emergence of artemisinin resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012 [epub ahead of print].
  • Cheeseman IH et al. A major genome region underlying artemisinin resistance in malaria. Science 2012 [epub ahead of print].

About the Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.

The Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme is one of the Wellcome Trust's Major Overseas Programmes, working to achieve the Trust's strategic priorities, which include combating infectious diseases.

About the University of Oxford's Medical Sciences Division
The University of Oxford’s Medical Sciences Division is recognised internationally for its outstanding research and teaching, attracting the brightest minds from all over the world. It is one of the largest biomedical research centres in Europe, with over 2500 people involved in research and more than 2800 students, and brings in around two-thirds of the University's external research income. Listed by itself, that would make it the fifth-largest university in the UK in terms of research grants and contracts.

Oxford is home to the UK's top-ranked medical school, and partnerships with the local NHS Trusts enable patients to benefit from the close links between medical research and healthcare delivery. 14 winners of the Nobel Prize for Physiology or Medicine worked or were educated at Oxford, and the Medical Sciences Division is home to 29 Fellows of the Royal Society and 68 Fellows of the Academy of Medical Sciences.

Wellcome Trust, Gibbs Building, 215 Euston Road, London NW1 2BE, UK T:+44 (0)20 7611 8888